Jay Bradner

Biography
Dr. James "Jay" Bradner joined Amgen in 2023 and currently serves as Executive Vice President, Research & Development, Artificial Intelligence & Data. He leads the company's global Research and Development organization, integrating biology, data science, and artificial intelligence to accelerate the discovery and development of innovative medicines. Under his leadership, Amgen is advancing a diverse pipeline of potential first- and best-in-class therapies across oncology, inflammation, general medicine, rare disease, and biosimilars. Immediately before joining Amgen, Dr. Bradner returned to clinical service as a stem cell transplant physician at the Dana-Farber Cancer Institute and Brigham & Women’s Hospital. He also taught at Harvard Business School and MIT, and served as an advisor to Blackstone Life Sciences and Isomorphic Labs (Alphabet, Google DeepMind). He previously served as President of the Novartis Institutes for BioMedical Research, where he was a member of the Executive Committee of Novartis. During his tenure, he built and led a highly productive research organization that combined advanced therapeutic platforms, large-scale data science and global scientific talent to drive innovation. His research and leadership have contributed to more than 100 new investigational medicines and more than 25 approved medicines. Earlier in his career, he was a clinician at the Dana-Farber Cancer Institute and an associate professor at Harvard Medical School. He co-authored more than 300 scientific publications and numerous U.S. patent applications. He also co-founded five biotechnology companies. Dr. Bradner is a graduate of Harvard College and the University of Chicago Pritzker School of Medicine. He completed a residency in Medicine at Brigham & Women's Hospital, fellowships in Medical Oncology and Hematology at the Dana-Farber Harvard Cancer Center, and postdoctoral training in Chemistry and Chemical Biology at Harvard University.